Pharmacological subgroup
M09A – ANDERE MITTEL GEGEN STÖRUNGEN DES MUSKEL- UND SKELETTSYSTEMS
5Decisions
20Patient groups
Added benefit by patient group
- Major2
- Considerable1
- Non-quantifiable4
- Not proven13
Subgroups
Decisions, newest first
- 2026-01-22DuvyzatGivinostatNon-quantifiable
- 2024-03-07EvrysdiRisdiplamNot proven: 3 of 3 patient groups
- 2021-11-04ZolgensmaOnasemnogen abeparvovecNot proven: 4 of 4 patient groups
- 2021-10-21EvrysdiRisdiplamNon-quantifiable: 2 of 6 patient groupsNot proven: 4 of 6 patient groups
- 2021-05-20SpinrazaNusinersenMajor: 2 of 6 patient groupsConsiderable: 1 of 6 patient groupsNon-quantifiable: 1 of 6 patient groupsNot proven: 2 of 6 patient groups
Data status: 2026-10-29